Josefa Leon

Dr. Josefa Leon

Hospital Clínico Universitario San Cecilio, Instituto de Investigación Biosanitaria, Granada, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2003 in Acta Biochimica Polonica
Verified
Journal Article
Open access
PDF file
Russel ReiterRussel Reiter
Russel Reiter
DTDun-Xian Tan
Dun-Xian Tan
JMJuan C Mayo
Juan C Mayo
RSRosa M Sainz
Rosa M Sainz
JLJosefa Leon
Josefa Leon
ZCZbigniew Czarnocki
Zbigniew Czarnocki
This brief resume enumerates the multiple actions of melatonin as an antioxidant. This indoleamine is produced in the vertebrate pineal gland, the retina and possibly some other organs. Additionally, however, it is found in invertebrates, bacteria, unicellular organisms as well as in plants, all of which do not have a pineal gland. Melatonin's functions as an antioxidant include: a), direct free radical scavenging, b), stimulation of antioxidative enzymes, c), increasing the efficiency of mitochondrial oxidative phosphorylation and reducing electron leakage (thereby lowering free radical generation), and 3), augmenting the efficiency of other antioxidants. There may be other functions of melatonin, yet undiscovered, which enhance its ability to protect against molecular damage by oxygen and nitrogen-based toxic reactants. Numerous in vitro and in vivo studies have documented the ability of both physiological and pharmacological concentrations to melatonin to protect against free radical destruction. Furthermore, clinical tests utilizing melatonin have proven highly successful; because of the positive outcomes of these studies, melatonin's use in disease states and processes where free radical damage is involved should be increased.

19 November 2004 in Journal of Pineal Research
Verified
Journal Article
Open access
PDF file
JLJosefa Leon
Josefa Leon
Dario Acuña-CastroviejoDario Acuña-Castroviejo
Dario Acuña-Castroviejo
Germaine EscamesGermaine Escames
Germaine Escames
DTDun‐Xian Tan
Dun‐Xian Tan
Russel ReiterRussel Reiter
Russel Reiter
Abstract:  Melatonin, or N‐acetyl‐5‐methoxytryptamine, is a compound derived from tryptophan that is found in all organisms from unicells to vertebrates. This indoleamine may act as a protective agent in disease conditions such as Parkinson's, Alzheimer's, aging, sepsis and other disorders including ischemia/reperfusion. In addition, melatonin has been proposed as a drug for the treatment of cancer. These disorders have in common a dysfunction of the apoptotic program. Thus, while defects which reduce apoptotic processes can exaggerate cancer, neurodegenerative disorders and ischemic conditions are made worse by enhanced apoptosis. The mechanism by which melatonin controls cell death is not entirely known. Recently, mitochondria, which are implicated in the intrinsic pathway of apoptosis, have been identified as a target for melatonin actions. It is known that melatonin scavenges oxygen and nitrogen‐based reactants generated in mitochondria. This limits the loss of the intramitochondrial glutathione and lowers mitochondrial protein damage, improving electron transport chain (ETC) activity and reducing mtDNA damage. Melatonin also increases the activity of the complex I and complex IV of the ETC, thereby improving mitochondrial respiration and increasing ATP synthesis under normal and stressful conditions. These effects reflect the ability of melatonin to reduce the harmful reduction in the mitochondrial membrane potential that may trigger mitochondrial transition pore (MTP) opening and the apoptotic cascade. In addition, a reported direct action of melatonin in the control of currents through the MTP opens a new perspective in the understanding of the regulation of apoptotic cell death by the indoleamine.

1 March 2001 in Journal of Pineal Research
Verified
Journal Article
Open access
PDF file
Dario Acuña-CastroviejoDario Acuña-Castroviejo
Dario Acuña-Castroviejo
MMMiguel Martín
Miguel Martín
MMManuel Macías
Manuel Macías
Germaine EscamesGermaine Escames
Germaine Escames
JLJosefa Leon
Josefa Leon
Russel ReiterRussel Reiter
Russel Reiter
Aerobic cells use oxygen for the production of 90–95% of the total amount of ATP that they use. This amounts to about 40 kg ATP/day in an adult human. The synthesis of ATP via the mitochondrial respiratory chain is the result of electron transport across the electron transport chain coupled to oxidative phosphorylation. Although ideally all the oxygen should be reduced to water by a four‐electron reduction reaction driven by the cytochrome oxidase, under normal conditions a small percentage of oxygen may be reduced by one, two, or three electrons only, yielding superoxide anion, hydrogen peroxide, and the hydroxyl radical, respectively. The main radical produced by mitochondria is superoxide anion and the intramitochondrial antioxidant systems should scavenge this radical to avoid oxidative damage, which leads to impaired ATP production. During aging and some neurodegenerative diseases, oxidatively damaged mitochondria are unable to maintain the energy demands of the cell leading to an increased production of free radicals. Both processes, i.e., defective ATP production and increased oxygen radicals, may induce mitochondrial‐dependent apoptotic cell death. Melatonin has been reported to exert neuroprotective effects in several experimental and clinical situations involving neurotoxicity and/or excitotoxicity. Additionally, in a series of pathologies in which high production of free radicals is the primary cause of the disease, melatonin is also protective. A common feature in these diseases is the existence of mitochondrial damage due to oxidative stress. The discoveries of new actions of melatonin in mitochondria support a novel mechanism, which explains some of the protective effects of the indoleamine on cell survival.

24 July 2000 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MMMiguel Martín
Miguel Martín
MMManuel Macías
Manuel Macías
Germaine EscamesGermaine Escames
Germaine Escames
JLJosefa Leon
Josefa Leon
Dario Acuña-CastroviejoDario Acuña-Castroviejo
Dario Acuña-Castroviejo
Mitochondria do not contain catalase and are therefore largely dependent on reduced glutathione (GSH) and glutathione peroxidases for its antioxidant protection. When GSH levels are greatly decreased, hydrogen peroxide accumulates leading to extensive mitochondrial damage. Melatonin has antioxidant properties and prevents toxic effects of reactive oxygen species by maintaining cellular GSH homeostasis. Thus, we examined the influence of melatonin and other classical antioxidants such as vitamins C and E on GSH content and the activity of the GSH‐related enzymes (glutathione peroxidase and reductase) in isolated rat liver and brain mitochondria treated with t‐butyl hydroperoxide (i‐BHP). In control mitochondria melatonin (100 nM) significantly increases GSH content and glutathione peroxidase and reductase activities. After incubation with 100 μM i‐BHP, the mitochondrial hydroperoxides level increased, 90% of mitochondrial GSH was oxidized to GSSH, and the activities of GSH‐related enzymes were almost totally inhibited. Melatonin (100 nM) counteracted the changes in GSH, GSH‐related enzymes and hydroperoxides induced by i‐BHP in cultured mitochondria. In the presence of 100 nM melatonin, the activity of the respiratory chain complexes I and IV, measured in submitochondrial particles prepared from rat liver and brain mitochondria, increased significantly. Vitamin C was virtually without effect, and only 1 mM vitamin E increased GSH and reduced hydroperoxide mitochondrial contents. Our results suggest that melatonin, but not vitamins C and E, prevents the toxic effects of hydroperoxides on mitochondria by regenerating their GSH content.

1 July 2004 in Life Sciences
Verified
Journal Article
Closed access
JLJosefa Leon
Josefa Leon
Dario Acuña-CastroviejoDario Acuña-Castroviejo
Dario Acuña-Castroviejo
Rosa M SainzRosa M Sainz
Rosa M Sainz
Juan MayoJuan Mayo
Juan Mayo
DTDun-Xian Tan
Dun-Xian Tan
RRRussel J Reiter
Russel J Reiter

1 August 2005 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
Juan MayoJuan Mayo
Juan Mayo
Rosa M SainzRosa M Sainz
Rosa M Sainz
DTDun-Xian Tan
Dun-Xian Tan
RHRüdiger Hardeland
Rüdiger Hardeland
JLJosefa Leon
Josefa Leon
RRRussel J. Reiter
Russel J. Reiter